Non-Insulin Therapies for Diabetes Market Report 2026

The non-insulin therapies for diabetes market size has grown strongly in recent years. It will grow from $21.21 billion in 2025 to $22.59 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to high prevalence of type 2 diabetes, reliance on oral hypoglycemic agents, limited patient adherence to insulin therapy, growth in hospital and retail pharmacy distribution, emergence of multiple drug classes.

The non-insulin therapies for diabetes market size is expected to see strong growth in the next few years. It will grow to $28.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rise in adoption of non-insulin drug combinations, increasing use of glp-1 and sglt2 inhibitors, expansion of online pharmacy channels, growing personalized and precision medicine approaches, advancing integration of digital health and remote monitoring. Major trends in the forecast period include rising adoption of personalized diabetes management, increasing use of ai-driven glucose monitoring systems, growing integration of telemedicine-linked therapy solutions, expanding implementation of data-driven clinical decision support, advancing deployment of connected devices for remote patient care.

The rising prevalence of diabetes is expected to drive the growth of the non-insulin therapies for diabetes market in the coming years. Diabetes is a chronic condition characterized by elevated blood glucose levels, occurring when the body is unable to produce sufficient insulin or properly utilize the insulin it produces. The increase in diabetes cases is fueled by factors such as sedentary lifestyles, unhealthy diets, genetic predisposition, aging populations, obesity, ethnicity, lack of awareness, limited access to healthcare, and environmental influences. Non-insulin therapies for diabetes work by improving insulin sensitivity, reducing hepatic glucose production, enhancing glucose uptake in muscle cells, and supporting overall glycemic control. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government agency, the GP-recorded prevalence of type 2 diabetes among adults aged 17 and over rose to 7%, up from 6.8% in March 2023. Therefore, the growing prevalence of diabetes is propelling the non-insulin therapies for diabetes market.

Major companies in the non-insulin therapies for diabetes market are focusing on developing advanced solutions, such as non-insulin GLP-1 receptor agonists, to expand treatment options, improve glycemic control, and strengthen their competitive position in diabetes and obesity management. Non-insulin GLP-1 receptor agonists are therapies that target GLP-1 receptors to regulate blood glucose and support weight reduction without the need for insulin. For example, in March 2025, Eli Lilly and Company, a U.S.-based pharmaceutical firm specializing in diabetes and metabolic disorders, launched Mounjaro (tirzepatide) in India following approval from the Central Drugs Standard Control Organisation. As a dual GIP and GLP-1 receptor agonist, Mounjaro addresses challenges in type 2 diabetes and obesity management through once-weekly subcutaneous administration, enhancing glycemic control, reducing appetite, slowing gastric emptying, and supporting significant weight loss, with dosing options starting at 2.5 mg and 5 mg to improve adherence and long-term outcomes.

In August 2023, Eli Lilly and Company acquired Sigilon Therapeutics Inc., a U.S.-based biopharmaceutical company, for $309.6 million. This acquisition allows Lilly to advance the development of encapsulated cell therapies, such as SIG-002, for treating type 1 diabetes, aiming to reduce the burden of continuous disease management for patients. Sigilon Therapeutics specializes in developing encapsulated cell therapies for type 1 diabetes treatment.

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC.

North America was the largest region in the non-insulin therapies for diabetes market in 2025. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-insulin therapies for diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the non-insulin therapies for diabetes market by raising costs of imported active pharmaceutical ingredients, specialized drug formulations, and advanced delivery devices. Segments such as glp-1 analogs, sglt2 inhibitors, and combination therapies are most affected, with North America, Europe, and Asia-Pacific seeing the highest impact. While tariffs increase production and procurement costs, they also drive local manufacturing initiatives, encourage development of cost-efficient drug alternatives, and strengthen domestic pharmaceutical supply chains.

The non-insulin therapies for diabetes market research report is one of a series of new reports that provides non-insulin therapies for diabetes market statistics, including non-insulin therapies for diabetes industry global market size, regional shares, competitors with a non-insulin therapies for diabetes market share, detailed non-insulin therapies for diabetes market segments, market trends and opportunities, and any further data you may need to thrive in the non-insulin therapies for diabetes industry. This non-insulin therapies for diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-insulin therapies for diabetes refer to medications and treatments used to manage blood glucose levels in diabetic patients without relying on insulin injections. These therapies are important for controlling blood sugar in patients who either do not require insulin or prefer alternative treatments.

The main drug classes in the non-insulin therapies for diabetes market include biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. Biguanides are oral hypoglycemic agents that manage type 2 diabetes by decreasing liver glucose production and improving insulin sensitivity. These medications are administered via oral and intramuscular routes and are distributed through channels such as retail pharmacies, hospital pharmacies, and online pharmacies. They are used for purposes including monitoring, diagnosis, treatment, and other related applications.

The non-insulin therapies for diabetes market consist of sales of glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, oral medications such as metformin and sulfonylureas, and injectable medications such as glp-1 receptor agonists. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.